Logo image of RNAZ

TRANSCODE THERAPEUTICS INC (RNAZ) Stock Analyst Earnings Estimates

NASDAQ:RNAZ - Nasdaq - US89357L4023 - Common Stock - Currency: USD

11.52  +0.42 (+3.78%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
RNAZ revenue by date.RNAZ revenue by date.
N/AN/AN/A
-100.00%
N/AN/A
180.81%
N/A
86.69%
EBITDA
YoY % growth
RNAZ ebitda by date.RNAZ ebitda by date.
N/AN/AN/A-6.109M-18.535M
-203.43%
-19.295M
-4.10%
-15.126M
21.61%
N/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
RNAZ ebit by date.RNAZ ebit by date.
-384K-456.9K
-18.98%
-726.6K
-59.03%
-6.151M
-746.56%
-18.634M
-202.93%
-19.419M
-4.21%
-15.661M
19.35%
N/A
21.84%
N/A
-36.67%
N/A
-39.63%
N/A
-14.41%
N/A
6.11%
N/A
42.28%
Operating Margin
RNAZ operating margin by date.RNAZ operating margin by date.
N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
RNAZ eps by date.RNAZ eps by date.
N/AN/AN/AN/AN/A
-61.45%
N/A
79.22%
-1,462.72
99.30%
N/A
99.70%
N/A
92.68%
N/A
25.00%
N/A
-158.33%
N/A
6.45%
N/A
41.38%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth
-1.67
99.75%
-1.04
99.30%
-0.80
99.47%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
N/AN/AN/A
EBIT
Q2Q % growth
-2.958M
42.16%
-3.162M
-46.02%
-3.468M
31.90%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2024
Q2Q % growth
-150.64
99.29%
-91.68-58.96-64.31%
Q3 2024
Q2Q % growth
-147.84
99.76%
-461.82313.9867.99%
Q2 2024
Q2Q % growth
-665.28
99.45%
-546.64-118.64-21.70%
Q1 2024
Q2Q % growth
-498.96 -659.74160.7824.37%
Q4 2023
Q2Q % growth
-21,104.16
92.86%
-10,178.78-10,925.38-107.33%
Q3 2023
Q2Q % growth
-62,092.80
74.55%
-56,548.80-5,544.00-9.80%
Q2 2023
Q2Q % growth
-121,598.40
54.31%
-127,800.296,201.894.85%
Q4 2022
Q2Q % growth
-295,680.00
-73.91%
-286,513.92-9,166.08-3.20%
Q3 2022
Q2Q % growth
-243,936.00
-121,967,900.00%
-301,593.6057,657.6019.12%
Q2 2022
Q2Q % growth
-266,112.00 -226,195.20-39,916.80-17.65%
Q4 2021
Q2Q % growth
-170,016.00 -188,496.0018,480.009.80%
RNAZ Yearly EPS VS EstimatesRNAZ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -200K -400K -600K -800K -1M
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2024
Q2Q % growth
306K-306K-100.00%
Q3 2024
Q2Q % growth
306K-306K-100.00%
RNAZ Yearly Revenue VS EstimatesRNAZ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2028 2029 2030 10M 20M 30M 40M 50M
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 0% 0% 0%
RevenueN/A N/A N/A N/A